Last reviewed · How we verify
Topical lyophilized exosomes application
Topical lyophilized exosomes application is a Exosome therapy Biologic drug developed by Instituto de Oftalmología Fundación Conde de Valenciana. It is currently FDA-approved for Ocular surface disease and corneal wound healing. Also known as: Exosomes.
Lyophilized exosomes delivered topically to the eye promote tissue repair and regeneration through delivery of bioactive molecules and stimulation of endogenous healing pathways.
Topical lyophilized exosomes have been studied as a potential treatment for skin aging, diabetic foot ulcers, and androgenic alopecia through clinical trials registered on ClinicalTrials.gov. The exact mechanism of action of topical lyophilized exosomes is currently unknown, according to ChEMBL.
At a glance
| Generic name | Topical lyophilized exosomes application |
|---|---|
| Also known as | Exosomes |
| Sponsor | Instituto de Oftalmología Fundación Conde de Valenciana |
| Drug class | Exosome therapy |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Exosomes are extracellular vesicles that carry proteins, lipids, and nucleic acids capable of modulating inflammation and promoting cellular regeneration. When applied topically to ocular tissues, they facilitate wound healing, reduce inflammation, and support tissue remodeling through paracrine signaling mechanisms. This approach leverages the natural regenerative properties of exosome-mediated cell-to-cell communication.
Approved indications
- Ocular surface disease and corneal wound healing
Common side effects
Key clinical trials
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia (NA)
- Effects on Facial Skin Aging After Topical Application of Exosomes With a Microneedling Device (PHASE4)
- Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical lyophilized exosomes application CI brief — competitive landscape report
- Topical lyophilized exosomes application updates RSS · CI watch RSS
- Instituto de Oftalmología Fundación Conde de Valenciana portfolio CI
Frequently asked questions about Topical lyophilized exosomes application
What is Topical lyophilized exosomes application?
How does Topical lyophilized exosomes application work?
What is Topical lyophilized exosomes application used for?
Who makes Topical lyophilized exosomes application?
Is Topical lyophilized exosomes application also known as anything else?
What drug class is Topical lyophilized exosomes application in?
What development phase is Topical lyophilized exosomes application in?
Related
- Drug class: All Exosome therapy drugs
- Manufacturer: Instituto de Oftalmología Fundación Conde de Valenciana — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Ocular surface disease and corneal wound healing
- Also known as: Exosomes
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing